Firdapse BioMarinLtd.

 

 

Von:                Adrian Quartel

Datum:           Donnerstag, 25. Februar 2010 12:22

An:                  freya-matthiessen-at-t-online.de;
                        Christian Look <CLook@bmrn.com>

Betreff:           Re: Zenas /Amifampridine

 

Dear Freya,

 

The Name Zenas will be changed to Firdapse.

 

Kind regards

Adrian

 

----- Original Message -----

From: freya-matthiessen@t-online.de <freya-matthiessen- at - t-online.de>

To: Adrian Quartel

Sent: Thu Feb 25 03:09:26 2010Subject: Zenas /Amifampridine

 

Dr. Adrian Quartel MD

 

            Director of Medical Affairs, EUMEA

            BioMarin Europe Ltd

...............

25 Feb 2010/

 

 

Dear Sir,

 

all sides concerned with the Lambert-Eaton-Syndrome are certainly very

pleased about the marketing authorisation for Zenas (3,4-Diaminopyridine)..

 

I am wondering, though, about the product name "Zenas" for Amifampridine.

Would you agree that the association with the statin "Zenas", although

already taken off market in 2001, might lead to confusions? Especially when

labelling requirements seem restricted as it is often the case with

blistered tablets / strip packs.

 

Could you kindly explain why "Zenas" was chosen as product name for

Amifampridine?

 

Sincerely

 

Freya Matthiessen

PF 2229

D-37012 Göttingen

freya-matthiessen-at-online.de

 

www.lems-mg.info